dc.contributor.author | Tas, Faruk | |
dc.contributor.author | Vatansever, Sezai | |
dc.contributor.author | Keskin, Sezai | |
dc.date.accessioned | 2021-03-02T21:56:33Z | |
dc.date.available | 2021-03-02T21:56:33Z | |
dc.date.issued | 2013 | |
dc.identifier.citation | Keskin S., Tas F., Vatansever S., "Adrenocortical carcinoma: clinicopathological features, prognostic factors and outcome.", Urologia internationalis, cilt.90, sa.4, ss.435-8, 2013 | |
dc.identifier.issn | 0042-1138 | |
dc.identifier.other | av_09c35a53-53fe-435c-9703-c247f9c21fd0 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/12353 | |
dc.identifier.uri | https://doi.org/10.1159/000345489 | |
dc.description.abstract | Objective: The purpose of this study was to investigate the clinicopathological characteristics and treatment outcomes of patients with adrenocortical carcinoma (AC). Methods: Twenty-four patients (10 females and 14 males) diagnosed with AC between 1998 and 2009 were evaluated. Clinical features and outcomes were reviewed. Results: Median age was 46.5 years. One (4%) patient was classified as stage I, 10 (42%) were classified as stage II, 8 (33%) were classified as stage III and 5 (21%) were classified as stage IV. Tumor sizes ranged from 3 to 22 cm with a mean diameter of 11 cm. Five patients were locally inoperable at initial diagnosis. In addition to surgery, 2 of 19 patients were treated with an adjuvant cisplatin plus etoposide regimen. Sixteen patients were treated with chemotherapy after recurrence. Median survival time was 18 months. The 1-and 5-year overall survival estimates were 73 and 48%, respectively. Mean survival times for male and female patients were 58 and 12 months, respectively (p = 0.046). Early T stage (p = 0.04), lymph node negativity (p < 0.001), the absence of distant metastases (p < 0.001) and early stage (p < 0.001) were cor-related with overall survival. Conclusion: AC is a rare disease with a poor prognosis. There are correlations between gender, stage and survival. Copyright (C) 2013 S. Karger AG, Basel | |
dc.language.iso | eng | |
dc.subject | Tıp | |
dc.subject | ÜROLOJİ VE NEFROLOJİ | |
dc.subject | Klinik Tıp | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | Nefroloji | |
dc.subject | İç Hastalıkları | |
dc.subject | Dahili Tıp Bilimleri | |
dc.subject | Sağlık Bilimleri | |
dc.title | Adrenocortical carcinoma: clinicopathological features, prognostic factors and outcome. | |
dc.type | Makale | |
dc.relation.journal | Urologia internationalis | |
dc.contributor.department | İstanbul Üniversitesi , , | |
dc.identifier.volume | 90 | |
dc.identifier.issue | 4 | |
dc.identifier.startpage | 435 | |
dc.identifier.endpage | 8 | |
dc.contributor.firstauthorID | 30099 | |